Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million
OTTAWA, Dec. 12, 2018 /CNW/ - The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the latest edition of the Market Intelligence Report: Anti-Vascular
Biologic anti-VEGFs are a fast growing class of drugs used to treat age-related macular degeneration (AMD) and other retinal conditions. AMD is the leading cause of visual impairment in adults over 50, with the more serious "wet" form affecting over 100,000 Canadians.
The report, which focuses on Lucentis and Eylea, the two anti-VEGF drugs approved for retinal conditions, also considers Avastin, an anti-VEGF cancer drug that has widespread off-label use for retinal diseases.
This is the second edition of the PMPRB's Market Intelligence Report series, each featuring a therapeutic class of drugs marked by relatively high-use and high-prices in Canada compared to foreign markets.
Follow us on Twitter: @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
Subscribe to our Free Newsletters!